Efficacy News and Research

RSS

Workshop on psychodrama therapy efficacy at iaedp Symposium 2012

Those suffering from eating disorders struggle with the idea of identity and self-image, unable to see clearly who they are emotionally and physically. During the presentation, "Psychodrama: Tools of Change" at the iaedp Symposium 2012, Mary Bellofatto, MA, LMHC, CEDS, TEP, NCC and Nancy Kirsner, PhD, M.Ed, OTR, TEP will lead a workshop on the efficacy of psychodrama therapy and how it can help patients overcome their struggle with one of the major stumbling blocks on the road to recovery.

30 Jan 2012

Susan Mallery finds breakthrough treatment for oral cancer

Dr. Susan Mallery, a professor in the College of Dentistry at The Ohio State University and Oral Pathology Consultant at the Ohio State University and James Cancer hospitals, has dedicated her nearly 30-year career to studying new strategies to preventing oral cancer.

30 Jan 2012

Scientists develop new vaccine to treat cancer at pre-clinical level

Scientists in Trinity College Dublin, Ireland, have developed a new vaccine to treat cancer at the pre-clinical level. The research team led by Professor Kingston Mills, Professor of Experimental Immunology at Trinity College Dublin discovered a new approach for treating the disease based on manipulating the immune response to malignant tumours.

27 Jan 2012

New system safe, effective in delivering CsA to organ transplant patients

A new system for delivering a drug to organ transplant patients, which could avoid the risk of harmful side effects, is being developed by scientists at the University of Strathclyde in Glasgow.

27 Jan 2012

FDA approves UCB's Keppra for treatment of partial onset seizures in infants

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Keppra (levetiracetam) tablets and oral solution as adjunctive therapy in the treatment of partial onset seizures in adults and children one month of age and older with epilepsy.

27 Jan 2012

Amorcyte commences enrollment in PreSERVE Phase 2 trial for acute myocardial infarction

Amorcyte, LLC, a NeoStem, Inc. company today announces the enrollment of the first patient in the Amorcyte PreSERVE Phase 2 trial for acute myocardial infarction.

25 Jan 2012

UH Case Medical Center initiates enrollment in Moxy Drug Coated Balloon trial for PAD

Physicians at University Hospitals (UH) Case Medical Center enrolled their first patient in LEVANT 2, a global, multicenter, randomized clinical trial evaluating the safety and efficacy of the Moxy™ Drug Coated Balloon for the treatment of peripheral arterial disease.

25 Jan 2012

One-year results from Covidien's EverFlex stent trial on P.A.D.

Covidien, a leading global provider of healthcare products, today announced that one-year results on the use of its EverFlex stent for superficial femoral artery stenting were presented here during the International Symposium on Endovascular Therapy (ISET) Conference.

25 Jan 2012

Sofie to receive U.S. patent for novel PET probes

Sofie Biosciences, Inc., offering a comprehensive range of products from pre-clinical PET imaging systems to new PET molecular imaging probes to better understand human disease, has been told that a U.S. Patent (8,101,740) will be granted by the United States Patent Office on technology that has been exclusively licensed to Sofie. The patent covers a family of novel PET probes, known as [18F]FAC.

25 Jan 2012

IHS experts develop new guidelines for migraine clinical trials

Experts from the International Headache Society (IHS) have developed new recommendations for conduct of acute and preventive migraine clinical trials. The third edition of Migraine Clinical Trials Guidelines is now available in the IHS journal Cephalalgia, which is published by SAGE.

25 Jan 2012

Aphios receives NIH's Phase II SBIR grant to develop APH-0703 for AD

Aphios Corporation has received a Phase II SBIR grant from the National Institutes of Health (NIH) amounting to $2.4 million over two years. The National Institute on Aging (NIA), part of the NIH, awarded the grant to the Aphios Corporation to develop an "Alzheimer's Disease Therapeutic."

24 Jan 2012

Genoscience, BioLineRx to develop and commercialize BL-8020 for HCV

BioLineRx, a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience, a French company focused on viral disease therapeutics, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C.

24 Jan 2012

Gilead commences GS-7340 Phase 2 trial in HIV

Gilead Sciences, Inc. today announced the initiation of a Phase 2 clinical trial evaluating GS-7340 for the treatment of HIV-1 infection in treatment-naïve adults. GS-7340 is a novel prodrug of tenofovir, the active agent in Viread.

24 Jan 2012

Covidien releases results of TurboHawk and SpiderFX combination study on P.A.D.

Covidien, a leading global provider of healthcare products, today released the results of the DEFINITIVE Ca++ study.

24 Jan 2012

ImmunoCellular initiates enrollment in ICT-107 Phase II trial for GBM in 23 centers

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

24 Jan 2012

Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's

Baxter International Inc. today provided an update on its clinical program evaluating the use of its GAMMAGARD LIQUID 10%, for the treatment of mild to moderate Alzheimer's disease.

From Baxter International Inc. 24 Jan 2012

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE(bortezomib), which updates the label to include the subcutaneous method of administration in all approved indications: multiple myeloma and mantle cell lymphoma after at least one prior therapy.

24 Jan 2012

PLC Systems initiates enrollment in RenalGuard pivotal trial for CIN

PLC Systems Inc., a company focused on innovative medical device technologies, announced the successful enrollment of the first patient in the CIN-RG trial, the company's pivotal trial to study the efficacy of its RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy.

24 Jan 2012

Patient enrollment complete in Enlivex Phase I/II clinical trial for autoimmune diseases

Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that the recruitment of 13 patients for the Enlivex Phase I/II clinical trial has been completed.

23 Jan 2012

Charité coordinates largest study in the world against common childhood cancer

Under an EU project now launched, Charité - Universitätsmedizin Berlin is coordinating the largest study in the world concerned with the fight against the most common type of cancer in children, acute lymphoblastic leukemia (ALL).

23 Jan 2012